Akt regulation of Aven contributes to the sensitivity of cancer cells to chemotherapeutic agents

Han,Kyoung‑Youn; Hwang,Jee  Won; Bae,Gyu‑Un; Kim,Su‑Nam; Kim,Yong  Kee

doi:10.3892/mmr.2015.3158

Akt regulation of Aven contributes to the sensitivity of cancer cells to chemotherapeutic agents

Authors:
- Kyoung‑Youn Han
- Jee Won Hwang
- Gyu‑Un Bae
- Su‑Nam Kim
- Yong Kee Kim
View Affiliations

Affiliations: Research Center for Cell Fate Control, College of Pharmacy, Sookmyung Women's University, Seoul 140‑742, Republic of Korea, Natural Products Research Center, Korea Institute of Science and Technology, Gangneung Institute, Gangneung, Gangwon‑do 210‑340, Republic of Korea
Published online on: January 8, 2015 https://doi.org/10.3892/mmr.2015.3158
Pages: 3866-3871

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, it was demonstrated that the protein level of the apoptosis inhibitor Aven is regulated by the Akt signaling pathway, evidenced by the observation that Aven levels were significantly increased in MCF7 constitutively active (CA)‑Akt cells and significantly inhibited following treatment with LY294002. This increase in Aven appears not to be mediated by transcriptional regulation and protein stabilization. However, the level of Aven was inversely correlated with the level of cathepsin D, which is a protease responsible for generating the C‑terminal of Aven, ΔN‑Aven, indicating that the level of Aven appears to be regulated by cathepsin D activity. It has previously been reported that ΔN‑Aven is the active form of Aven, which functions as an anti‑apoptotic molecule. Notably, low levels of ΔN‑Aven were detected in MCF7 CA‑Akt cells, which were more sensitive to anticancer drugs. Taken together, the current results suggest that the expression of Aven is regulated by the Akt signaling pathway through cathepsin D activity, which contributes to the sensitivity of cancer cells to chemotherapeutic agents.

View Figures

View References

1	Rich T, Allen RL and Wyllie AH: Defying death after DNA damage. Nature. 407:777–783. 2000. View Article : Google Scholar : PubMed/NCBI
2	Roos WP and Kaina B: DNA damage-induced cell death by apoptosis. Trends Mol Med. 12:440–450. 2006. View Article : Google Scholar : PubMed/NCBI
3	Bernstein C, Bernstein H, Payne CM and Garewal H: DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 511:145–178. 2002. View Article : Google Scholar : PubMed/NCBI
4	Herr I and Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood. 98:2603–2614. 2001. View Article : Google Scholar : PubMed/NCBI
5	Sanchez-Prieto R, Rojas JM, Taya Y and Gutkind JS: A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 60:2464–2472. 2000.PubMed/NCBI
6	Okada H and Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 4:592–603. 2004. View Article : Google Scholar : PubMed/NCBI
7	Maddika S, ande SR, Panigrahi S, et al: Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 10:13–29. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chau BN, Cheng EH, Kerr DA and Hardwick JM: Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell. 6:31–40. 2000. View Article : Google Scholar : PubMed/NCBI
9	Kutuk O, Temel SG, Tolunay S and Basaga H: Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. Eur J Cancer. 46:2494–2505. 2010. View Article : Google Scholar : PubMed/NCBI
10	Melzer IM, Fernandez SB, Bosser S, et al: The Apaf-1-binding protein Aven is cleaved by Cathepsin D to unleash its anti-apoptotic potential. Cell Death Differ. 19:1435–1445. 2012. View Article : Google Scholar : PubMed/NCBI
11	Guo JY, Yamada A, Kajino T, et al: Aven-dependent activation of ATM following DNA damage. Curr Biol. 18:933–942. 2008. View Article : Google Scholar : PubMed/NCBI
12	Esmaili AM, Johnson EL, Thaivalappil SS, Kuhn HM, Kornbluth S and Irusta PM: Regulation of the ATM-activator protein Aven by CRM1-dependent nuclear export. Cell Cycle. 9:3913–3920. 2010. View Article : Google Scholar : PubMed/NCBI
13	Choi J, Hwang YK, Sung KW, et al: Aven overexpression: association with poor prognosis in childhood acute lymphoblastic leukemia. Leuk Res. 30:1019–1025. 2006. View Article : Google Scholar : PubMed/NCBI
14	Eissmann M, Melzer IM, Fernandez SB, et al: Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms. Oncogene. 32:2586–2591. 2013. View Article : Google Scholar
15	Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
16	Jo SK, Hong JY, Park HJ and Lee SK: Anticancer activity of novel daphnane diterpenoids from daphne genkwa through cell-cycle arrest and suppression of Akt/STAT/Src signalings in human lung cancer cells. Biomol Ther (Seoul). 20:513–519. 2012. View Article : Google Scholar
17	Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
18	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
19	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
20	Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
21	Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283. 2000. View Article : Google Scholar : PubMed/NCBI
22	Lothstein L, Israel M and Sweatman TW: Anthracycline drug targeting: cytoplasmic versus nuclear - a fork in the road. Drug Resist Updat. 4:169–177. 2001. View Article : Google Scholar
23	Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 65:95–106. 2000.
24	El Maalouf G, Le Tourneau C, Batty GN, Faivre S and Raymond E: Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev. 35:167–174. 2009. View Article : Google Scholar
25	Tamburrino A, Piro G, Carbone C, Tortora G and Melisi D: Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 4:562013. View Article : Google Scholar : PubMed/NCBI
26	Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI